Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials” [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233] (Contemporary Clinical Trials Communications (2023) 36, (S2451865423001795), (10.1016/j.conctc.2023.101233))
Publication date
2024-04
Authors
Hollander, Bibiche den
Rothuizen-Lindenschot, Marieke
Geertjens, Lisa
Vaz, Frédéric M.
Brands, Marion M.
Le, Hoang Lan
van Eeghen, Agnies M.
van de Ven, Peter M.
Cornel, Martina C.
Jacobs, Bart A W
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by
Abstract
The authors regret the need for the following corrigendum: In table 1, the amino acid change for the patient is listed incorrectly. It should be p.(Arg696Leu) instead of p.(Arg820Leu). The authors would like to apologise for any inconvenience caused.
Keywords
Pharmacology
Citation
Hollander, B D, Rothuizen-Lindenschot, M, Geertjens, L, Vaz, F M, Brands, M M, Le, H L, van Eeghen, A M, van de Ven, P M, Cornel, M C, Jacobs, B A W, Bruining, H & van Karnebeek, C D 2024, 'Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation : Rationale and protocol for single patient (n-of-1) multiple cross-over trials” [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233] (Contemporary Clinical Trials Communications (2023) 36, (S2451865423001795), (10.1016/j.conctc.2023.101233))', Contemporary clinical trials communications, vol. 38, 101264. https://doi.org/10.1016/j.conctc.2024.101264